Baxter acquires EU licence to rigosertib from Oncanova
Baxter International Inc. and Onconova Therapeutics Inc.have announced that they have entered into a European licensing agreement for rigosertib, a novel targeted anti-cancer compound from Onconova currently in a Phase III study for the treatment of a group of rare hematologic malignancies called Myelodysplastic Syndromes and in a Phase II/III study for Pancreatic Cancer. Under the terms of the agreement, Baxter will obtain commercialization rights in the European Union and other countries in Europe.
Rigosertib's mechanism of action targets dual pathways (PI-3K and PLK) critical to the growth of cancer cells. It has been studied in more than 600 patients worldwide and has shown activity in treating both solid tumors and hematological malignancies. Rigosertib is currently being evaluated in a Phase III clinical trial in 270 MDS patients who have failed or relapsed after receiving current therapeutic options, with initial results expected in the second half of 2013.
Under the terms of the agreement, Baxter will obtain commercialization rights in the European Union and other countries in EuropeLearning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.